2023年9月9日,来自德国纽伦堡弗里德里希-亚历山大大学神经科的研究者们在Nature Communications上发表了题为“PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation...
帕博利珠单抗单药治疗为程序性死亡配体-1(PD-L1)阳性 [PD-L1肿瘤细胞阳性比例分数(TPS)≥1%]、EGFR敏感突变或ALK重排阴性的晚期/转移性非小细胞肺癌(NSCLC)患者带来临床获益,美国批准其用于PD-L1 TPS ≥1%患者,欧盟批准其用于PD-L1 TPS ≥50%患者。国际、随机、开放标签、III期KEYNOTE-042研究显示,与含铂化疗...
[3] Herbst, R.S., P. Baas, D.W. Kim, et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2...
2 Kazutaka Hosoya1, Daichi Fujimoto, Takeshi Morimoto, et al. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-smallcell lung cancer patients: a retrospective multicenter study[J]. BMC Cancer, ...
[14]. Herbst RS, Garon EB, Kim DW, et al. 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC. WCLC 2020, abstract FP13.01 [15]. Long GV., Long-Term Survival From Pembrolizumab Retreatment: Phase 3 KEYNOTE-006 in...
[20]MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-l1-positive advanced gastric cancer (keynote012): a multicentre, open-label, phase 1b trial[J]. The Lancet Oncology, 2016, 17(6): 717-726. DOI: 10.1016/s1470-2045(16)00175-3. ...
[14]. Herbst RS, Garon EB, Kim DW, et al. 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC. WCLC 2020, abstract FP13.01 [15]. Long GV., Long-Term Survival From Pembrolizumab Retreatment: Phase 3 KEYNOTE-006 in...
定义:任何强度 PD-L1 膜染色肿瘤细胞占肿瘤细胞的百分比。 计算方法: CPS 英文:Combined Positive Score 中文:联合阳性分数 定义:每 100 个肿瘤细胞中 PD-L1 染色的肿瘤细胞和肿瘤相关的免疫数之和。 计算方法: IPS 英文:Immune cell Proportion Score
2、CPS:综合阳性评分(Combined Positive Score) CPS=(PD-L1膜染色阳性肿瘤细胞+ PD-L1 膜染色阳性肿瘤相关免疫细胞(淋巴细胞、巨噬细胞))/总肿瘤细胞数 x100 3、TC:肿瘤细胞阳性率 TC=(任何强度PD-L1膜染色阳性肿瘤细胞数/总肿瘤细胞数)x100% 4、IC:肿瘤相关免疫细胞阳性率 IC=(任何强度PD-L1膜染色阳性的...
非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识 01 引言 近年来,以程序性死亡受体1(programmed death-1, PD-1)/PD配体1(PD ligand 1, PD-L1)免疫检查点抑制剂为主的免疫治疗在晚期肺癌中取得了突破性的进展,改变了该领域的治疗格局,为患者带来了更多生存获益。虽然对于免疫治疗适宜人群筛选和疗效预测的生物...